39 studies found for:    " August 18, 2010":" September 17, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" August 18, 2010":" September 17, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (39 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Text Messaging to Improve Adherence to Clinic Visits and Reduce Early Resumption of Sexual Intercourse After Male Circumcision
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome;   Circumcision, Male;   Patient Compliance;   Cellular Phone
Intervention: Other: Text Message
2 Completed
Has Results
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Etravirine;   Drug: Ritonavir;   Drug: Darunavir
3 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Etravirine
4 Completed
Has Results
Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients
Condition: HIV Infections
Intervention:
5 Recruiting R5 Integrase Study in HIV-1 Naive Patients
Condition: HIV Infections
Intervention: Drug: Raltegravir and Maraviroc in combination
6 Unknown  The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
Conditions: Human Immunodeficiency Virus (HIV);   Hepatitis C, Chronic
Intervention:
7 Completed Could Dietary Algae Affect Immunity and Viral Counts in People With HIV?
Condition: HIV Infections
Intervention: Other: seaweed
8 Completed A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 WBM Capsule;   Drug: GSK2248761 WBM Tablet Formulation 1;   Drug: GSK2248761 WBM Tablet Formulation 2;   Drug: GSK2248761 WBM Tablet Formulation 3;   Drug: GSK2248761 WBM Tablet
9 Completed Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults
Condition: HIV
Intervention: Behavioral: Effectiveness of different strategies in HIV testing and linkage to care
10 Completed The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance
Conditions: HIV-infection;   Pregnancy;   Mother to Child Transmission
Intervention: Drug: phenytoin
11 Terminated Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
Conditions: HIV Infection;   Mitochondrial Dysfunction
Interventions: Drug: Atazanavir/ritonavir;   Drug: Efavirenz
12 Completed Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia
Conditions: HIV Infection;   Tuberculosis;   Immunosuppression
Intervention:
13 Completed A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)
Conditions: Sexually Transmitted Infections;   HIV Infections
Intervention: Behavioral: Experimental
14 Active, not recruiting Affect Management for Early Adolescents
Condition: HIV Infections
Interventions: Behavioral: Affect Management;   Behavioral: General Health Promotion
15 Completed
Has Results
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Conditions: Hepatitis C Infection;   HIV Infection
Intervention: Drug: Nitazoxanide With Pegylated Interferon And Ribavirin
16 Terminated A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: YASMIN;   Drug: GSK2248761;   Other: Placebo
17 Recruiting ZIAGEN® Post-marketing Surveillance
Condition: Infection, Human Immunodeficiency Virus I
Intervention: Drug: ZIAGEN®
18 Completed GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: GSK1349572;   Drug: Fosamprenavir;   Drug: Ritonavir
19 Completed Atripla to Raltegravir Switch Study
Condition: HIV Infection
Intervention: Drug: Truvada/Raltegravir
20 Active, not recruiting Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study
Conditions: Hiv Infection;   Lung Cancer
Intervention: Radiation: Low dose computed tomography (CT)

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Indicates status has not been verified in more than two years